Literature DB >> 8432180

Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia.

K S Marvin1, R D Spellberg.   

Abstract

A 72-year-old physician with myeloid metaplasia developed marked thrombocytosis, pulmonary hypertension, and right heart failure following splenectomy. No cause for the pulmonary hypertension could be found. The pulmonary hypertension and right heart failure returned to normal when hydroxyurea therapy corrected the thrombocythemia. It is concluded that thrombocytosis may cause pulmonary hypertension, mediated by pulmonary capillary obstruction from cellular components, involving platelet aggregation, microthrombosis, and stasis, and possible vasoconstrictor effects.

Entities:  

Mesh:

Year:  1993        PMID: 8432180     DOI: 10.1378/chest.103.2.642

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

1.  [Pulmonary hypertension in chronic myeloproliferative disorders].

Authors:  B M Einsfelder; K-M Müller
Journal:  Pathologe       Date:  2005-05       Impact factor: 1.011

2.  Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms.

Authors:  Emir C Roach; Margaret M Park; W H Wilson Tang; James D Thomas; Kewal Asosingh; Matt Kalaycio; Serpil C Erzurum; Samar Farha
Journal:  J Heart Lung Transplant       Date:  2014-09-28       Impact factor: 10.247

Review 3.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

4.  Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders.

Authors:  Ranju Gupta; Sirisha Perumandla; Yelena Patsiornik; Selvanayagam Niranjan; Anju Ohri
Journal:  J Natl Med Assoc       Date:  2006-11       Impact factor: 1.798

5.  Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.

Authors:  Matthew Austin; Peter J Quesenberry; Corey E Ventetuolo; Olin Liang; John L Reagan
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-05-13

6.  Cardiovascular Manifestations of Myeloproliferative Disorders: A Review of the Literature.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Hosp Physician       Date:  1999-07

7.  Cardiac Complications of Myeloproliferative Disorders.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Resid Staff Physician       Date:  2001-07

Review 8.  Vascular complications after splenectomy for hematologic disorders.

Authors:  Shelley E Crary; George R Buchanan
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

Review 9.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

10.  Pulmonary hypertension diagnosed by echocardiography during idiopathic myelofibrosis. A case report and a brief review of the literature.

Authors:  Claudio Perrone; Roberto Cartolari; Beatrice Lupi; Sergio Morelli
Journal:  Multidiscip Respir Med       Date:  2010-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.